- Home
- CLDX vs PENN Comparison
CLDX vs PENN Comparison
Compare CLDX & PENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLDX | PENN |
|---|---|---|
| Founded | N/A | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 1995 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CLDX | PENN |
|---|---|---|
| Price | $33.93 | $21.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 13 |
| Target Price | ★ $46.60 | $20.83 |
| AVG Volume (30 Days) | 913.4K | ★ 3.5M |
| Earning Date | 05-04-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $12,743,000.00 | ★ $6,362,900,000.00 |
| Revenue This Year | $111.39 | $6.85 |
| Revenue Next Year | $235.85 | $3.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 87.78 | N/A |
| 52 Week Low | $19.52 | $11.65 |
| 52 Week High | $35.83 | $22.36 |
Technical Indicators
Market Signals| Indicator | CLDX | PENN |
|---|---|---|
| Relative Strength Index (RSI) | 62.80 | 65.49 |
| Support Level | $28.51 | $13.58 |
| Resistance Level | $35.10 | $22.36 |
| Average True Range (ATR) | 1.23 | 0.87 |
| MACD | 0.43 | -0.12 |
| Stochastic Oscillator | 78.89 | 79.30 |
Price Performance
Historical ComparisonAbout CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About PENN PENN Entertainment Inc.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 42 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 81% of total sales in 2025; 19% was from the interactive segment, which includes sports, i-gaming, and media revenue. The retail portfolio generates low-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media asset, theScore, provides access to sports betting/i-gaming technology and clientele, helping it form a leading digital position.